The tetravalent bispecific antibody AFM13 engages and primes innate immune cells for anti-cancer immunity

被引：0
|
作者：
Pahl, Jens
Koch, Joachim
Reusch, Uwe
Gantke, Thorsten
Cerwenka, Adelheid
Treder, Martin
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-2997
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2997
引用
收藏
页数：2
相关论文
共 36 条
  • [1] RECRUIT-TANDABS: ENGAGING IMMUNE CELLS TO KILL CANCER CELLS --AFM13: A BISPECIFIC TETRAVALENT TANDAB FOR TREATING HODGKIN LYMPHOMA
    Rajkovic, E.
    Hucke, C.
    Knackmuss, S.
    Molkenthin, V.
    Reusch, U.
    Legall, F.
    Little, M.
    ANNALS OF ONCOLOGY, 2011, 22 : 240 - 241
  • [2] AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
    Jingjing Wu
    Jiaping Fu
    Mingzhi Zhang
    Delong Liu
    Journal of Hematology & Oncology, 8
  • [3] AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
    Wu, Jingjing
    Fu, Jiaping
    Zhang, Mingzhi
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [4] AFM13, a novel bispecific (CD30xCD16A) tetravalent antibody (TandAb®) specifically engaging NK-cells to fight Hodgkin Lymphoma (HL)
    Marschner, J-P
    Treder, M.
    Kohrt, H. E.
    Topp, M. S.
    Engert, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 28 - 28
  • [5] Cord Blood Derived Natural Killer Cells Loaded with a Tetravalent Bispecific Antibody Construct (AFM13) As Off-the-Shelf Cell Therapy for CD30+Malignancies
    Kerbauy, Lucila
    Kaplan, Mecit
    Banerjee, Pinaki P.
    Lorraine, Francesca
    Lim, Wei Inng
    Cortes, Ana Karen Nunes
    Daher, May
    Mendt, Mayela Carolina
    Basar, Rafet
    Li, Li
    Muftuoglu, Muharrem
    Shaim, Hila
    Shanley, Mayra
    Liu, Enli
    Ang, Sonny
    Cai, Rong
    Nandivada, Vandana
    Champlin, Richard E.
    Koch, Joachim
    Treder, Martin
    Shpall, Elizabeth J.
    Rezvani, Katy
    BLOOD, 2018, 132
  • [6] Understanding the anti-cancer immune response: Innate and adaptive responses to cancer cells
    Loi, S.
    BREAST, 2023, 68 : S3 - S3
  • [7] Innate-like T cells: A promising asset in anti-cancer immunity
    Molgora, Martina
    Colonna, Marco
    CANCER CELL, 2022, 40 (07) : 714 - 716
  • [8] A Phase I Study with the Bispecific Anti-CD30 x Anti-CD16A Antibody Construct AFM13 in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Rothe, Achim
    Younes, Anas
    Reiners, Katrin S.
    Dietlein, Markus
    Eichenauer, Dennis A.
    Kessler, Joerg
    Topp, Max S.
    Hummel, Horst
    Ravic, Miroslav
    Hucke, Christian
    von Strandmann, Elke Pogge
    Engert, Andreas
    BLOOD, 2011, 118 (21) : 1585 - 1585
  • [9] A Phase I Study Of An Anti-CD30 x Anti-CD16A Bispecific Tandab Antibody, AFM13, In Patients With Relapsed Or Refractory Hodgkin Lymphoma
    Zhukovsky, Eugene
    Rothe, Achim
    von Tresckow, Bastian
    Topp, Max
    Younes, Anas
    Eichenauer, Dennis A.
    Hummel, Horst
    Reiners, Katrin S.
    Dietlein, Markus
    Kessler, Joerg
    Ravic, Miroslav
    Hucke, Christian
    Strandmann, Elke Poggevon
    Engert, Andreas
    BLOOD, 2013, 122 (21)
  • [10] A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
    Rothe, Achim
    Sasse, Stephanie
    Topp, Max S.
    Eichenauer, Dennis A.
    Hummel, Horst
    Reiners, Katrin S.
    Dietlein, Markus
    Kuhnert, Georg
    Kessler, Joerg
    Buerkle, Carolin
    Ravic, Miroslav
    Knackmuss, Stefan
    Marschner, Jens-Peter
    von Strandmann, Elke Pogge
    Borchmann, Peter
    Engert, Andreas
    BLOOD, 2015, 125 (26) : 4024 - 4031
1234